中穎電子(300327.SZ):控股子公司股東昇力、雋創擬將芯穎科技8%股權轉讓予永曜集團
格隆匯11月22日丨中穎電子(300327.SZ)公佈,公司控股子公司芯穎科技有限公司(“芯穎科技”)系由公司與上海輝黎電子科技合夥企業(有限合夥)、昇力投資有限公司(“昇力”)和雋創有限公司(“雋創”)共同投資設立。公司目前持有芯穎科技69.2%股權(對應出資額人民幣8650萬元),芯穎科技系公司控股子公司。
昇力、雋創擬分別將其持有的芯穎科技3.2%股權(對應出資額人民幣400萬元)和4.8%股權(對應出資額人民幣600萬元)轉讓給永曜集團有限公司(“永曜集團”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.